2025年1-6月非经营性资金占用及其他关联资金往来情况汇总表 上市公司名称：成都康弘药业集团股份有限公司 单位：万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 | 上市公司核算的会 | 2025年期初占用资金 | 2025年1-6月占用累计发 | 2025年1-6月占用资金 | 2025年1-6月偿还累计 | 2025年6月30日占用资 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关联关系 | 计科目 | 余额 | 生金额（不含利息） | 的利息 | 发生金额 | 金余额 | | | | 控股股东、实际控制人及其附属企业 | 无 | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际控制人及其附属企业 | 无 | | | | | | | | | | | 小计 | | | | | | | | | | | | 其他关联方及附属企业 | 无 | | | | | | | | | | | 小计 | ...

证券代码：002773 证券简称：康弘药业 公告编号：2025-044 成都康弘药业集团股份有限公司 第八届监事会第十二次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 经审核，监事会认为：董事会编制和审核的公司《2025 年半年 度报告》及摘要的程序符合法律、行政法规和中国证监会的规定，报 告内容真实、准确、完整地反映了公司的实际情况，不存在任何虚假 记载、误导性陈述或者重大遗漏。同意通过该报告，并同意据此出具 监事会对公司《2025 年半年度报告》及摘要无异议的书面审核意见。 《2025 年半年度报告》于 2025 年 8 月 28 日披露在公司指定信 息披露媒体巨潮资讯网（http://www.cninfo.com.cn）；《2025 年半 年度报告摘要》于 2025 年 8 月 28 日披露在公司指定信息披露媒体《证 券时报》《中国证券报》《上海证券报》《证券日报》及巨潮资讯网 （http://www.cninfo.com.cn）。 2. 会议以3票同意，0票反对，0票弃权审议通过了《2025年半年 度募集资金存放及使用情况的专项报告》。 ...

证券代码：002773 证券简称：康弘药业 公告编号：2025-043 成都康弘药业集团股份有限公司 第八届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 成都康弘药业集团股份有限公司（以下简称"公司"）第八届董 事会第十二次会议于2025年8月27日在公司会议室通过现场和通讯相 结合的方式召开。会议通知已于2025年8月17日以书面、传真或电子 邮件等形式向所有董事发出。本次董事会应到董事九名，实到董事九 名（其中：董事王霖先生、独立董事周德敏先生、邓宏光先生、许楠 女士以通讯方式参加），会议由董事长柯尊洪先生主持，公司监事、 董事会秘书及高级管理人员列席了会议。本次会议的召开符合《中华 人民共和国公司法》和《成都康弘药业集团股份有限公司章程》的有 关规定。 二、董事会会议审议情况 会议以书面记名投票方式表决通过了如下决议： 1. 会议以9票赞成、0票反对、0票弃权审议通过了《2025年半年 度报告及摘要》。 《2025 年半年度报告》于 2025 年 8 月 28 日披露在公司指定信 1 / 4 息披露媒 ...

成都康弘药业集团股份有限公司 2025 年半年度报告全文 成都康弘药业集团股份有限公司 2025 年半年度报告 2025-047 2025 年 8 月 1 成都康弘药业集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人柯尊洪、主管会计工作负责人钟建军及会计机构负责人(会计 主管人员)何映梅声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司在本报告"第三节管理层讨论与分析 十、公司面临的风险和应对措 施"中描述了公司未来经营中可能面临的风险，敬请投资者认真阅读，注意 投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | . | . | 4 | | --- | --- | --- | | 1 | | | | 第一节 | 重要提示、目录和释义 | 2 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | 6 | | ...

Group 1 - The core viewpoint is that the expectation of a Federal Reserve interest rate cut is boosting sentiment in the pharmaceutical sector, with the Medical Innovation ETF (516820.SH) rising by 1.04% [1] - Key stocks such as Haisco (002653), Baili Tianheng (688506), and Kanghong Pharmaceutical (002773) saw significant increases of 4.86%, 3.97%, and 3.91% respectively [1] - The U.S. July core CPI rose by 0.3%, slightly exceeding expectations, while inflation for tariff-sensitive goods remained moderate, reinforcing the expectation of a 25 basis point rate cut in September [1] Group 2 - Longjiang Securities noted that despite the typical vacation period for overseas pharmaceutical executives in July and August, there has been a notable acceleration in overseas expansion, with Chinese innovative drugs reaching $30 billion in exports in just one and a half months [2] - The acceleration in overseas expansion is attributed to pressures in the overseas industry and an increase in the "new" content of domestic innovative drugs [2] - The expectation of a weaker U.S. economy and employment data is likely to accelerate the pace of Federal Reserve rate cuts, enhancing global liquidity and benefiting technology stocks, which may provide an opportunity for investors to capitalize on the rebound in core pharmaceutical assets through the Medical Innovation ETF (516820) [2]

人民财讯8月12日电，8月12日晚间，康弘药业（002773）官微发布声明称，近日，公司获悉有不法分子 冒用康弘药业名义，通过恶意使用康弘药业名称虚构投资产品项目，从事诈骗等严重违法活动。康弘药 业提示，公司从未开展任何投资产品的销售，也从未通过任何渠道、以任何形式、向任何第三方授权进 行投资产品的销售。针对上述不法行为，康弘药业提出严正警告，并将向有关机关进行举报，同时保留 向相关不法分子追究法律责任的权利。 ...

Core Viewpoint - The company is currently in the clinical III phase for its traditional Chinese medicine product KH110, aimed at treating Alzheimer's disease, amidst increasing concerns about the rising prevalence of Alzheimer's and depression in China [2] Company Research - KH110, the company's drug for Alzheimer's disease, is in the clinical III phase [2] - The company has acknowledged the growing population of Alzheimer's patients and the decreasing age of onset [2] - There is an indication of increased investment in research and development related to depression, reflecting the rising number of depression cases in the country [2]

证券代码：002773 证券简称：康弘药业 公告编号：2025-042 成都康弘药业集团股份有限公司 关于使用自有资金购买理财产品的公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确和完 | | --- | | 整，没有虚假记载、误导性陈述或重大遗漏。 | 成都康弘药业集团股份有限公司（以下简称"康弘药业"或"公司"） 第八届董事会第十次会议和二〇二四年度股东会审议通过了《关于使用 自有资金购买理财产品的议案》，同意公司及下属子公司使用部分闲置 自有资金在不超过人民币38亿元的额度内购买理财产品（包括结构性存 款），购买原则为安全性高、流动性好、由商业银行发行并提供保本承 诺的短期保本型理财产品（包括结构性存款），购买期限为自股东会审 议通过之日起一年；在上述额度及期限内，资金可以滚动使用；董事会 授权公司总裁或财务负责人根据上述原则行使具体理财产品的购买决策 权，由财务部负责具体购买事宜，具体内容详见公司指定信息披露媒体 和巨潮资讯网（www.cninfo.com.cn）刊登于2025年4月26日《第八届董 事会第十次会议决议公告》（公告编号：2025-010）、《关于使用自有 资金购买理财产品的 ...

Group 1 - The core point of the article is that Kanghong Pharmaceutical (002773) has announced that its traditional Chinese medicine product KH110, aimed at treating Alzheimer's disease, is currently in the clinical phase III [1] - The company encourages stakeholders to pay attention to future developments regarding the drug [1] - The article highlights that the outcomes and timelines for drug research, clinical trials, evaluations, and approvals are subject to uncertainty [1]

Investment Rating - The report maintains a strong investment rating for the pharmaceutical and biotechnology sector, indicating it is expected to outperform the market [7]. Core Insights - The report highlights the recent policy push for brain-computer interface (BCI) technology, emphasizing the potential for a trillion-dollar market opportunity. The government aims to cultivate 2-3 global leading companies in this field by 2030, showcasing the urgency to position within this emerging industry [4][16][17]. Market Review - The CITIC Pharmaceutical Index fell by 0.8% during the week of August 4-8, 2025, underperforming the CSI 300 Index by 2.0 percentage points. However, since the beginning of 2025, the CITIC Pharmaceutical and Biotechnology Index has risen by 21.8%, outperforming the CSI 300 Index by 17.5 percentage points [3][31]. - The top five performing stocks during this week included Nanmo Biology (+42.5%), Haichen Pharmaceutical (+41.3%), Sainuo Medical (+39.5%), Chengyi Pharmaceutical (+35.8%), and Dabo Medical (+31.5%) [3][48]. Investment Focus - The report suggests focusing on innovative drugs, particularly those with revenue and commercialization capabilities, as well as medical devices, which are expected to see a policy turning point. The report encourages identifying high-performing stocks as companies begin to disclose mid-year results [5][16]. - Specific companies to watch include Mailland, Xiangyu Medical, Chengyitong, Innovation Medical, and Sanbo Brain Science, which are positioned well within the BCI sector [4][16][17]. Policy Developments - Recent policies from seven ministries, including the Ministry of Industry and Information Technology, outline a clear development roadmap for BCI technology, covering aspects from technical breakthroughs to global competitiveness [4][18][22]. - By 2027, key technological breakthroughs are expected, with the establishment of an advanced technical and industrial system. The BCI market is projected to grow significantly, with the global medical BCI market expected to reach $40 billion by 2030 and $145 billion by 2040 [22][23]. Company Developments - Notable companies in the BCI space include: - **Qiangnao Technology**: Focused on non-invasive BCI, received FDA approval for its smart bionic hand. - **Nerve Tiger Technology**: Achieved real-time motion decoding and language understanding with its invasive BCI technology. - **Mikron Medical**: Developing a range of non-invasive BCI products and collaborating with hospitals for research [29][30]. This summary encapsulates the key points from the industry report, focusing on investment opportunities, market performance, and policy developments within the pharmaceutical and biotechnology sectors, particularly in relation to brain-computer interfaces.